Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source

home / insights / breaking-barriers-safely-targeting-obstructive-hypertrophic-cardiomyopathy

Anjali Tiku Owens, MD, emphasizes the role of novel Cardiac Myosin inhibitors (CMI) in the treatment of patients with obstructive hypertrophic cardiomyopathy. She discusses recent clinical trial data, exciting ongoing clinical trials. and gives an in depth overview of how to safely prescribe the first approved CMI, mavacamten, for obstructive hypertrophic cardiomyopathy.

© 2024 MJH Life Sciences

All rights reserved.